Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
In many cases, the end of the year gives you time to step back and take stock of the last 12 months. This is when many of us take a hard look at what worked and what did not, complete performance reviews, and formulate plans for the coming year. For me, it is all of those things plus a time when I u...
SYS-CON.TV
Apogenix's Apocept™ for Glioblastoma Multiforme Named One of "Top 10 Projects to Watch"

HEIDELBERG, Germany, Nov. 6, 2012 /PRNewswire/ -- Apogenix, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, today announced that its lead product, Apocept™ (APG101), has been selected by Elsevier Business Intelligence and Windhover Conferences as one of oncology's "Top 10 Projects To Watch." This announcement is in conjunction with the "Therapeutic Area Partnerships" conference event taking place in Boston from Nov. 28 to 30. Apogenix's CEO, Thomas Hoeger, Ph.D., will be presenting an overview on Apogenix's controlled Phase 2 study of Apocept in patients with recurrent glioblastoma multiforme (GBM) on Nov. 29.

"We are honored that our lead candidate, Apocept, has been selected as one of Windhover's Top 10 Projects to Watch," said Dr. Hoeger. "Apocept is the first drug in more than a decade that has shown clear benefits in a randomized, controlled clinical trial regarding quality of life, progression free survival as well as overall survival in patients with recurrent GBM, a disease that represents a tremendous unmet medical need. Best responses were seen in patients expressing a newly identified biomarker. Apocept's unique mechanism of action has potential in many other cancers beyond GBM."

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive oncology opportunities the industry has to offer," said David Cassak, Vice President, Content, Windhover Conferences, a division of Elsevier Business Intelligence. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."

About Apogenix
Apogenix, a spin-out from the German Cancer Research Center (DKFZ), is developing novel protein therapeutics for the treatment of cancer and inflammatory diseases based either on the targeted modulation of apoptosis (programmed cell death) or on blocking the growth of tumour cells. The company's lead product candidate Apocept (APG101) is being developed for the treatment of glioblastoma, the most common and aggressive type of primary brain tumour. In 2013, an additional clinical study with Apocept will be initiated in patients suffering from myelodysplastic syndromes. Since its inception in 2005, the company has raised more than €50 million with dievini Hopp BioTech Holding GmbH & Co. KG as main investor, and has been awarded public grants totaling over € 8 million. Apogenix is based in Heidelberg, Germany.

About Apocept (APG101)
The company's lead product candidate, Apocept, a first-in-class, fully human fusion protein combining the extracellular domain of the CD95 receptor and the Fc portion of IgG, successfully completed a phase 1 study in 2009. In December 2009, Apogenix started a controlled phase 2 trial with the compound for the treatment of recurrent glioblastoma. The patient recruitment for this study was completed in September 2011. The primary endpoint as well as a number of secondary endpoints of the trial were successfully reached in 2012. Apogenix was granted orphan drug designation for Apocept in 2009 for the treatment of glioblastoma in Europe and in the US.

About Glioblastoma
Glioblastoma is the most frequent and aggressive brain tumour belonging to the group of gliomas. The tumour cells show a high resistance to radiation and chemotherapy. They spread and infiltrate the neighboring tissue so quickly that eradicative surgery is often impossible. Due to the diffuse infiltration into brain tissue, recurrence is often experienced within months after initial treatment. Approximately 28,000 new cases of malignant glioma are diagnosed in the US and EU each year (Source: US National Cancer Registry). The current standard therapy focuses on surgery, followed by radiotherapy and chemotherapy. The relative survival rate for adults diagnosed with glioblastoma is less than 30% within one year of diagnosis. Only 3% of patients live longer than five years after primary diagnosis (Source: Central Brain Tumor Registry of the United States) showing the high unmet medical need in this indication. Currently, there are no approved treatment options available for recurrent glioblastoma patients with proven efficacy data from an actively controlled clinical trial.

Contact

Dr. Thomas Hoeger

CEO/CFO

Apogenix GmbH

D-69120 Heidelberg, Germany

Phone: +49 (6221) 5 86 08-0

Email: contact@apogenix.com

www.apogenix.com


Media Contacts                              

U.S.A.

Europe

Martina Schwarzkopf, Ph.D.

Raimund Gabriel

Russo Partners

MC Services AG 

Phone: + 1 (212) 845 4292

Phone: +49 (89) 210 228 30

martina.schwarzkopf@russopartnersllc.com 

raimund.gabriel@mc-services.eu

SOURCE Apogenix

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

SOA World Latest Stories
AppZero, a fast, flexible way to move enterprise applications to the cloud, has announced that AppZero Cloud Edition is available to try on Amazon Web Services (AWS) free of charge, as an AWS Test Drive. AppZero's award-winning application migration tool enables users to move server a...
The 4th International DevOps Summit, co-located with16th International Cloud Expo – being held June 9-11, 2015, at the Javits Center in New York City, NY – announces that its Call for Papers is now open. Born out of proven success in agile development, cloud computing, and process aut...
There is little doubt that Big Data solutions will have an increasing role in the Enterprise IT mainstream over time. 7th International Big Data Expo, co-located with 16th International Cloud Expo – to be held June 9–11, 2015, at the Javits Center in New York City, NY, announces its Ca...
14th International Cloud Expo, held on June 10–12, 2014 at the Javits Center in New York City, featured three content-packed days with a rich array of sessions about the business and technical value of cloud computing, Internet of Things, Big Data, and DevOps led by exceptional speaker...
People often ask how Qubell is different from Chef, Puppet, OpenShift, Docker, Heat, Ansible, Mesos, Kubernetes or some other hip product du jour. Like any comparison of apples to oranges, the answer involves a surprisingly deep investigation into botanical conventions, differences bet...
Appcore automates the business of cloud computing by delivering cloud automation management platforms for enterprise private clouds and service provider public clouds. Appcore AMP™ is cloud automation designed to simplify cloud environments through a single management and monitoring in...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON Featured Whitepapers
ADS BY GOOGLE